Press Releases Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Year All Years 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Keywords Go Advanced Search Search Search Headlines Only From To Asset Types Photos Video Audio Documents Events Standard Nov 14, 2024 Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 Nov 6, 2024 Evofem Secures Investor Support for Proposed Merger through Voting Agreements Oct 28, 2024 Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem Sep 20, 2024 Aditxt’s Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025 Sep 9, 2024 Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024 Aug 20, 2024 Evofem Biosciences Addresses the Impact of GLP-1 Medications on Oral Contraceptive Absorption and Introduces Phexxi as a Non-Oral Solution Aug 14, 2024 Evofem Biosciences Announces Financial Results for the Second Quarter of 2024 Jul 25, 2024 Evofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1st Jul 23, 2024 Evofem Signs Phexxi® License Agreement for Middle East with Pharma 1 Jul 15, 2024 Lupin Divests U.S. Commercial Women's Health Specialty Business - SOLOSEC - to Evofem Biosciences Jun 27, 2024 Hello Alpha Partners with Evofem to Offer Phexxi® as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare Photos 1 Jun 11, 2024 Evofem Announces Issuance of New U.S. Patent Covering Phexxi Composition of Matter May 15, 2024 Evofem Biosciences Announces Financial Results for the First Quarter of 2024 Apr 18, 2024 Evofem Strengthens Phexxi Intellectual Property with New Composition of Matter Patent From USPTO Mar 27, 2024 Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023 Mar 20, 2024 Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-Cal Mar 7, 2024 For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy Feb 1, 2024 Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023 Jan 8, 2024 Washington State HCA Removes Prior Authorization for Hormone-Free "In the Moment" Contraceptive PHEXXI Ahead of Huskies vs. Wolverines Championship Game Dec 12, 2023 Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi®, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive Health Needs of Women Globally Nov 14, 2023 Evofem Biosciences Announces Financial Results for the Third Quarter of 2023 Oct 24, 2023 Evofem Biosciences Announces Preliminary Results for the Third Quarter of 2023 Oct 13, 2023 Evofem to Participate in the Virtual Investor Ask the CEO Conference Sep 27, 2023 Evofem Announces Padagis Will Not Seek FDA Approval to Market a Generic Version of Phexxi® Until Evofem's Phexxi Patents Expire Sep 11, 2023 Evofem Biosciences Successfully Amends S.P.A. with Institutional Investor Show 5102550100 per page«12345678910»
